RGLS-8429 is an antisense oligonucleotide commercialized by Regulus Therapeutics, with a leading Phase I program in Polycystic Kidney Disease. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RGLS-8429’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for RGLS-8429 is expected to reach an annual total of $173 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RGLS-8429 Overview
See Also:
Regulus Therapeutics Overview
Regulus Therapeutics (Regulus) is a biopharmaceutical company that focuses on the discovery and development of microRNA-based therapeutics for orphan kidney diseases such as autosomal dominant polycystic kidney diseases. Its pipeline products include ADPKD is developed for the treatment of autosomal dominant polycystic kidney disease. It offers services such as clinical trials. The company is also evaluating therapies against infectious diseases and central nervous system disorders. It utilizes its proprietary microRNA development platform to discover and develop its therapies for cancer, fibrosis, metabolic and inflammatory disorders. Regulus Therapeutics is headquartered in San Diego, California, the US.
The operating loss of the company was US$28.2 million in FY2022, compared to an operating loss of US$27.8 million in FY2021. The net loss of the company was US$28.3 million in FY2022, compared to a net loss of US$27.8 million in FY2021.
For a complete picture of RGLS-8429’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
